BioSpace News Archive

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its second quarter and first six months of 2023 financial results on Thursday, August 3, 2023 after the close of the U.S. financial markets.

DexCom, Inc. reported its financial results as of and for the quarter ended June 30, 2023.

Senseonics Holdings, Inc. announced that it plans to release its second quarter 2023 financial results after market close on Thursday, August 10, 2023.

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended June 30, 2023.

Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced financial results for the quarter ended June 30, 2023.

Nyxoah SA, a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea, announced that the Company will participate in the Canaccord Genuity 43rd Growth Conference, which takes place August 7 – 10, 2023 in Boston, Massachusetts.

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”) today announced that the Company will release financial results for the second quarter of 2023 on Tuesday, August 8, 2023, after market close.

Cellectis S.A. (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS) today announced that it will report financial results for the second quarter ended June 30, 2023 on Thursday, August 3, 2023 after the close of the US market.

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, announced that Peter Powchik, M.D., will join Vaxxinity’s leadership team as Executive Vice President, Global Scientific Director starting October 1, 2023.

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, announced that it is commencing an underwritten public offering of $60,000,000 of shares of its common stock.